{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:26:31Z","timestamp":1791588391346,"version":"4.3.4"},"reference-count":23,"publisher":"Georg Thieme Verlag KG","issue":"02","funder":[{"name":"The Pennsylvania Department of Health State","award":["#04100000330"],"award-info":[{"award-number":["#04100000330"]}]},{"name":"CTRC\/CTSI","award":["NIH\/NCRR\/CTSA UL-1 RR024153"],"award-info":[{"award-number":["NIH\/NCRR\/CTSA UL-1 RR024153"]}]},{"name":"Vascular Medicine Institute","award":["706654 (MVR)"],"award-info":[{"award-number":["706654 (MVR)"]}]},{"name":"University of Pittsburgh Provost Technology Development Fund","award":["TDF OTM 10024 (MVR)"],"award-info":[{"award-number":["TDF OTM 10024 (MVR)"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2013]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Desmopressin (DDAVP) is the treatment of choice in those with mild von Willebrand disease (VWD), yet 20% are unresponsive to DDAVP, and among the 80% who respond, the response is transient, as endothelial stores are depleted after three days. We, therefore, conducted a single-center Phase II clinical trial to determine safety and biologic efficacy of recombinant interleukin-11 (rhIL-11, Neumega\u00ae) in patients with VWD unresponsive or allergic to DDAVP, or mild or moderate haemophilia A (HA). Increases in VWF:RCo were observed by 48 hours after rhIL-11, with a 1.54-fold increase by Day 4, 1.30-fold in VWD and 1.73-fold in HA. Similarly, by 48 hours, increases in VIII:C were observed, with a 1.65-fold increase by Day 4, 1.86-fold in VWD and 1.48-fold in HA. Platelet VWFmRNA expression by qPCR increased 0.81-fold but did not correlate with plasma VWF:Ag responses. rhIL-11 was well tolerated, with grade 1 or less fluid retention, flushing, conjunctival erythema, except for transient grade 3 hyponatraemia in one subject after excess fluid intake for diabetic hyperglycaemia, which resolved with fluid restriction. In summary, rhIL-11 increases VWF levels in two of four DDAVP-unresponsive or allergic VWD and F.VIII levels in four of five mild or moderate haemophilia A subjects, suggesting its potential use in treatment of these disorders.<\/jats:p>","DOI":"10.1160\/th12-06-0447","type":"journal-article","created":{"date-parts":[[2012,12,14]],"date-time":"2012-12-14T09:13:32Z","timestamp":1355476412000},"page":"248-254","source":"Crossref","is-referenced-by-count":21,"title":["Phase II prospective open-label trial of recombinant interleukin-11 in desmopressin-unresponsive von Willebrand disease and mild or moderate haemophilia A"],"prefix":"10.1160","volume":"109","author":[{"given":"Enrico","family":"Novelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anila","family":"Murshed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Merricks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kloos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Nichols","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Ragni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2017,11,29]]},"reference":[{"key":"10.1160\/TH12-06-0447-1","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V69.2.454.454","volume":"69","author":"Rodeghiero","year":"1987","journal-title":"Blood"},{"key":"10.1160\/TH12-06-0447-2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1055\/s-0038-1651576","volume":"69","author":"Ginsburg","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1160\/TH12-06-0447-3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.02146.x"},{"key":"10.1160\/TH12-06-0447-4","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1055\/s-0037-1613992","volume":"84","author":"Sadler","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1160\/TH12-06-0447-5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01643.x"},{"key":"10.1160\/TH12-06-0447-6","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood.V90.7.2515","volume":"90","author":"Mannucci","year":"1997","journal-title":"Blood"},{"key":"10.1160\/TH12-06-0447-7","unstructured":"Medical Product Safety. In Healthy People 2010: A Systematic Approach to Health Improvement. 2003; 17: 3-19. Available at: http:\/\/www.healthypeople.gov. (Accessed February 13, 2012)"},{"key":"10.1160\/TH12-06-0447-8","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1200\/JCO.1997.15.11.3368","volume":"15","author":"Isaacs","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1160\/TH12-06-0447-9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01827.x"},{"key":"10.1160\/TH12-06-0447-10","doi-asserted-by":"publisher","DOI":"10.1160\/TH11-04-0274"},{"key":"10.1160\/TH12-06-0447-11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0464"},{"key":"10.1160\/TH12-06-0447-12","first-page":"420","volume":"119","author":"Benson","year":"1992","journal-title":"J Lab Clin Med"},{"key":"10.1160\/TH12-06-0447-13","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.19.12.3055"},{"key":"10.1160\/TH12-06-0447-14","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood.V81.10.2644.2644","volume":"81","author":"Nichols","year":"1993","journal-title":"Blood"},{"key":"10.1160\/TH12-06-0447-15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2937"},{"key":"10.1160\/TH12-06-0447-16","unstructured":"National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.03, June 14, 2010. Available at: http:\/\/ctep.cancer.gov\/forms\/CTCAEv4.pdf. (Accessed February 13, 2012)"},{"key":"10.1160\/TH12-06-0447-17","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00190.x"},{"key":"10.1160\/TH12-06-0447-18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200008173430702"},{"key":"10.1160\/TH12-06-0447-19","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1160\/TH-09-02-0104","volume":"102","author":"Luxembourg","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1160\/TH12-06-0447-20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0290"},{"key":"10.1160\/TH12-06-0447-21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.2.465"},{"key":"10.1160\/TH12-06-0447-22","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/blood.V87.9.3615.bloodjournal8793615","volume":"87","author":"Gordon","year":"1996","journal-title":"Blood"},{"key":"10.1160\/TH12-06-0447-23","first-page":"3607","volume":"87","author":"Tepler","year":"1996","journal-title":"Blood"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1160\/TH12-06-0447.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T19:38:06Z","timestamp":1595101086000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1160\/TH12-06-0447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":23,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2017,12,4]]},"published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1160\/th12-06-0447","relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}